Galectin-3 is a 32- to 35-kDa member of the galectin family of b-galactoside-binding lectins, which is characterized by a carbohydrate recognition domain. Through its carbohydrate-binding function, it regulates cell growth, differentiation, and inflammation. It also plays a complex, context-dependent role in the kidneys. During the development, it promotes nephrogenesis and is strongly expressed in the ureteric bud and its derivatives. An increase in the concentration of galectin-3 has been reported to be associated with fibrosis of the kidneys. Elevated levels of plasma galectin-3 are also associated with increased risks of rapid renal function decline, incident chronic kidney disease, and progressive renal impairment, and also with cardiovascular endpoints, infection, and all-cause mortality in patients with renal function impairment. This review discusses a general survey on galectin-3 expressions in nephrogenesis, kidney injury in animal models, clinical renal diseases, and renal transplantation and the potential role of galectin-3 for treatment in kidney disease.
BarondesS.H., CooperD.N., GittM.A., LefflerH.Galectins. Structure and function of a large family of animal lectins.J Biol Chem.1994; 269: 20807–20810.
2.
CummingsR.D., LiuF.T.Galectins. In Essentials of Glycobiology, 2nd ed.; VarkiA., CummingsR.D., EskoJ.D., FreezeH.H., StanleyP., BertozziC.R., HartG.W., EtzlerM.E., eds.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA.2009.
3.
KasaiK., HirabayashiJ.Galectins: A family of animal lectins that decipher glycocodes.J Biochem.1996; 119: 1–8.
4.
DavidsonP.J., DavisM.J., PattersonR.J., RipocheM.A., PoirierF., WangJ.L.Shuttling of galectin-3 between the nucleus and cytoplasm.Glycobiology.2002; 12: 329–937.
5.
HsuD.K., LiuF.T.Regulation of cellular homeostasis by galectins.Glycoconj J.2004; 19: 507–515.
6.
OchiengJ., FurtakV., LukyanovP.Extracellular functions of galectin-3.Glycoconj J.2004; 19: 527–535.
7.
DumicJ., DabelicS., FlogelM.Galectin-3: An open-ended story.Biochim Biophys Acta.2006; 1760: 616–635.
8.
De BoerR.A., VoorsA.A., MuntendamP., van GilstW.H., van VeldhuisenD.J.Galectin-3: A novel mediator of heart failure development and progression.Eur J Heart Fail.2009; 11: 811–817.
9.
HendersonN.C., SethiT.The regulation of inflammation by galectin-3.Immunol Rev.2009; 230: 160–171.
10.
SakakiM., FukumoriT., FukawaT.. Clinical significance of Galectin-3 in clear cell renal cell carcinoma.J Med Investig.2010; 57: 152–157.
11.
StraubeT., ElliA.F., GrebC.. Changes in the expression and subcellular distribution of galectin-3 in clear cell renal cell carcinoma.J Exp Clin Cancer Res.2011; 30: 89.
12.
MeniniS., IacobiniC., Blasetti FantauzziC., PesceC.M., PuglieseG.Role of galectin-3 in obesity and impaired glucose homeostasis.Oxid Med Cell Longev.2016; 2016: 9618092.
13.
DhirapongA., LleoA., LeungP., GershwinM.E., LiuF.T.The immunological potential of galectin-1 and -3.Autoimmun Rev.2009; 8: 360–363.
14.
FeldmanC.Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.J Lab Clin Med.2004; 143: 269–283.
15.
BicharaM., Attmane-ElakebA., BrownD.. Exploring the role of galectin 3 in kidney function: A genetic approach.Glycobiology.2006; 16: 36–45.
16.
WinyardP.J., BaoQ., HughesR.C., WoolfA.S.Epithelial galectin-3 during human nephrogenesis and childhood cystic diseases.J Am Soc Nephrol.1997; 8: 1647–1657.
17.
BullockS.L., JohnsonT.M., BaoQ., HughesR.C., WinyardP.J., WoolfA.S.Galectin-3 modulates ureteric bud branching in organ culture of the developing mouse kidney.J Am Soc Nephrol.2001; 12: 515–523.
18.
IacobiniC., MeniniS., OddiG.. Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: Evidence for a protective role of galectin-3 as an AGE receptor.FASEB J.2004; 18: 1773–1775.
19.
NishiyamaJ., KobayashiS., IshidaA.. Up-regulation of galectin-3 in acute renal failure of the rat.Am J Pathol.2000; 157: 815–823.
20.
LohrM., KaltnerH., LenschM., AndreS., SinowatzF., GabiusH.J.Cell-type-specific expression of murine multifunctional galectin-3 and its association with follicular atresia/luteolysis in contrast to pro-apoptotic galectins-1 and -7.Histochem Cell Biol.2008; 130: 567–581.
21.
DiamondJ.R.Macrophages and progressive renal disease in experimental hydronephrosis.Am J Kidney Dis.1995; 26: 133–140.
22.
HendersonN.C., MackinnonA.C., FarnworthS.L.. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis.Am J Pathol.2008; 172: 288–298.
KikuchiY., KobayashiS., HemmiN.. Galectin-3-positive cell infiltration in human diabetic nephropathy.Nephrol Dial Transplant.2004; 19: 602–607.
25.
KangE.H., MoonK.C., LeeE.Y.. Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis.Lupus.2009; 18: 22–28.
26.
EnsrudK.E., LuiL.Y., TaylorB.C.. Renal function and risk of hip and vertebral fractures in older women.Arch Intern Med.2007; 167: 133–139.
27.
McClellanW.M., FlandersW.D.Risk factors for progressive chronic kidney disease.J Am Soc Nephrol.2003; 14: S65–S70.
28.
PerkovicV., CassA., PatelA.A.. High prevalence of chronic kidney disease in Thailand.Kidney Int.2008; 73: 473–479.
29.
TanakaH., ShiohiraY., UezuY., HigaA., IsekiK.Metabolic syndrome and chronic kidney disease in Okinawa, Japan.Kidney Int.2006; 69: 369–374.
30.
WeinerD.E., TighiouartH., AminM.G.. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies.J Am Soc Nephrol.2004; 15: 1307–1315.
31.
De ZeeuwD., RamjitD., ZhangZ.. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL.Kidney Int.2006; 69: 1675–1682.
32.
TangW.H., ShresthaK., ShaoZ.. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.Am J Cardiol.2011; 108: 385–390.
33.
O'SeaghdhaC.M., HwangS.J., HoJ.E., VasanR.S., LevyD., FoxC.S.Elevated galectin-3 precedes the development of CKD.J Am Soc Nephrol.2013; 24: 1470–1477.
34.
lacobiniC., AmadioL., OddiG.. Role of galectin-3 in diabetic nephropathy.J Am Soc Nephrol.2003; 14: S264–S270.
35.
DrechslerC., DelgadoG., WannerC.. Galectin-3, renal function, and clinical outcomes: Results from the LURIC and 4D studies.J Am Soc Nephrol.2015; 26: 2213–2221.
36.
ArendS.M., MallatM.J., WestendorpR.J., van der WoudeF.J., van EsL.A.Patient survival after renal transplantation; more than 25 years follow-up.Nephrol Dial Transplant.1997; 12: 1672–1679.
37.
TanR., LiuX., WangJ.. Alternations of galectin levels after renal transplantation.Clin Biochem.2014; 47: 83–88.
38.
DangZ., MacKinnonA., MarsonL.P., SethiT.Tubular atrophy and interstitial fibrosis after renal transplantation is dependent on galectin-3.Transplantation.2012; 93: 477–484.
SunZ.L., MaC.J., JinH., YuanY., LiuN.F.Effects of advanced glycosylation end products and rosiglitazone on the expression and secretion of galectin-3 in human renal mesangial cells.Chin Med J.2009; 122: 1067–1071.
41.
Kolatsi-JoannouM., PriceK.L., WinyardP.J., LongD.A.Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury.PLoS ONE.2011; 6: e18683.
42.
De BoerR.A., VoorsA.A., MuntendamP., van GilstW.H., van VeldhuisenD.J.Galectin-3: a novel mediator of heart failure development and progression.Eur J Heart Fail.2009; 11: 811–817.
43.
SharmaU.C., PokharelS., Van BrakelT.J.. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.Circulation.2004; 110: 3121–3128.
44.
ReifenbergK., LehrH.A., TorzewskiM.. Interferon- gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice.Am J Pathol.2007; 171: 463–472.
45.
OikonomouE., TousoulisD., SiasosG., ZaromitidouM., PapavassiliouA.G., StefanadisC.The role of inflammation in heart failure: new therapeutic approaches.Hellenic J Cardiol.2011; 52: 30–40.
46.
WeberK.T., GerlingI.C., KianiM.F.. Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets.Curr Drug Targets.2003; 4: 505–516.
47.
PsarrasS., MavroidisM., SanoudouD.. Regulation of adverse remodelling by osteopontin in a genetic heart failure model.Eur Heart J.2012; 33: 1954–1963.
48.
LinY.H., LinL.Y., WuY.W.. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.Clin Chim Acta.2009; 409: 96–99.
49.
SharmaU.C., PokharelS., van BrakelT.J.. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.Circulation.2004; 110: 3121–3128.
50.
KrenningG., ZeisbergE.M., KalluriR.The origin of fibroblasts and mechanism of cardiac fibrosis.J Cell Physiol.2010; 225: 631–637.
51.
HendersonN.C., MackinnonA.C., FarnworthS.L.. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis.Am J Pathol.2008; 172: 288–298.
52.
LokD.J., LokS.I., Bruggink-André de la PorteP.W.. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure.Clin Res Cardiol.2012; 102: 103–110.
53.
YilmazH., GurelO.M., CelikH.T.. Relationship of galectin-3 to left ventricular geometry and hypertrophy in chronic hemodialysis patients.Herz.2015; 40(4): 702–708.
54.
FelkerG.M., FiuzatM., ShawL.K.. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.Circ Heart Fail.2012; 5: 72–78.
55.
De BoerR.A., LokD., HillegeJ.L.. Clinical and prognostic value of galectin-3, a novel fibrosis-associated biomarker. Relation with clinical and biochemical correlates of heart failure.J Am Coll Cardiol.2010; 55: A26.
56.
JanuzziJ.L.Jr., CamargoC.A., AnwaruddinS.. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study.Am J Cardiol.2005; 95: 948–954.
57.
Van KimmenadeR.R., JanuzziJ.L.Jr., EllinorP.T.. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.J Am Coll Cardiol.2006; 48: 1217–1224.
58.
De BoerR.A., LokD.J., JaarsmaT.. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.Ann Med.2011; 43: 60–68.
59.
KindermannM., ReilJ.C., PieskeB., van VeldhuisenD.J., BöhmM.Heart failure with normal left ventricular ejection fraction: what is the evidence?Trends Cardiovasc Med.2008; 18: 280–292.
60.
PaulusW.J., TschöpeC., SandersonJ.E.. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology.Eur Heart J.2007; 28: 2539–2550.
61.
HoJ.E., LiuC., LyassA.. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.J Am Coll Cardiol.2012; 60: 1249–1256.
62.
De BoerR.A., Van VeldhuisenD.J., GansevoortR.T.. The fibrosis marker Galectin-3 and outcome in the general population.J Intern Med.2012; 272: 55–64.
63.
De BoerR.A., EdelmannF., Cohen-SolalA., MamasM.A., MaiselA., PieskeB.Galectin-3 in heart failure with preserved ejection fraction.Eur J Heart Fail.2013; 15: 1095–1101.
64.
VlassaraH., LiY.M., ImaniF.. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex.Mol Med.1995; I: 634–646.
65.
HegabZ., GibbonsS., NeysesL., MamasM.A.Role of advanced glycation end products in cardiovascular disease.World J Cardiol.2012; 4: 90–102.
66.
WeigertJ., NeumeierM., WanningerJ.. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes.J Clin Endocrinol Metab.2010; 95: 1404–1411.
67.
ClementyN., BenhendaN., PiverE.. Serum galectin-3 levels predict recurrences after ablation of atrial fibrillation.Sci Rep.2016; Sep 28; 6: 34357.
68.
LokD.J., Van Der MeerP., de la PorteP.W.. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.Clin Res Cardiol.2010; 99: 323–328.
69.
GopalD.M., KommineniM., AyalonN.. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.J Am Heart Assoc.2012; 1: e000760.
70.
MannD.L.Inflammatory mediators in heart failure: homogeneity through heterogeneity.Lancet.1999; 353: 1812–1813.
71.
KangE.H., MoonK.C., LeeE.Y.. Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis.Lupus.2009; 18: 22–28.
